129 related articles for article (PubMed ID: 32407536)
1. Optimization of a Low-Cost, Sensitive PNA Clamping PCR Method for JAK2 V617F Variant Detection.
Di Francia R; Crisci S; Muto T; Giancola C; Petriccone L; Catapano O; Cummarro A; Pinto A; Frigeri F
J Appl Lab Med; 2020 Jul; 5(4):643-655. PubMed ID: 32407536
[TBL] [Abstract][Full Text] [Related]
2. Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR.
Kinz E; Leiherer A; Lang AH; Drexel H; Muendlein A
Int J Lab Hematol; 2015 Apr; 37(2):217-24. PubMed ID: 24963593
[TBL] [Abstract][Full Text] [Related]
3. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases.
Rapado I; Albizua E; Ayala R; Hernández JA; Garcia-Alonso L; Grande S; Gallardo M; Gilsanz F; Martinez-Lopez J
Ann Hematol; 2008 Sep; 87(9):741-9. PubMed ID: 18575865
[TBL] [Abstract][Full Text] [Related]
4. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
[TBL] [Abstract][Full Text] [Related]
5. Peptide nucleic acid probe-based fluorescence melting curve analysis for rapid screening of common JAK2, MPL, and CALR mutations.
Park J; Song M; Jang W; Chae H; Lee GD; Kim K; Park H; Kim M; Kim Y
Clin Chim Acta; 2017 Feb; 465():82-90. PubMed ID: 27939919
[TBL] [Abstract][Full Text] [Related]
6. Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory.
Merker JD; Jones CD; Oh ST; Schrijver I; Gotlib J; Zehnder JL
J Mol Diagn; 2010 Jan; 12(1):58-64. PubMed ID: 19959796
[TBL] [Abstract][Full Text] [Related]
7. A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation.
Tan AY; Westerman DA; Dobrovic A
Am J Clin Pathol; 2007 Jun; 127(6):977-81. PubMed ID: 17509995
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a tetra-primer amplification refractory mutation system-polymerase chain reaction combined with melting analysis-assay for clinical JAK2 V617F mutation detection.
Liu W; Hu T; Chen Y; Zhang X; Gu X; Guan M
Mol Diagn Ther; 2014 Oct; 18(5):579-85. PubMed ID: 25015634
[TBL] [Abstract][Full Text] [Related]
9. [Usefulness of real-time semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening].
Chae H; Lee JH; Lim J; Jung SW; Kim M; Kim Y; Han K; Cho BS; Cho SG; Lee JW; Min WS
Korean J Lab Med; 2009 Jun; 29(3):243-8. PubMed ID: 19571623
[TBL] [Abstract][Full Text] [Related]
10. Detection of acquired Janus kinase 2 V617F mutation in myeloproliferative disorders by fluorescence melting curve analysis.
Reading NS; Lim MS; Elenitoba-Johnson KS
Mol Diagn Ther; 2006; 10(5):311-7. PubMed ID: 17022694
[TBL] [Abstract][Full Text] [Related]
11. A tetra-primer polymerase chain reaction approach for the detection of JAK2 V617F mutation.
Koksal V; Etlik O; Arican-Baris ST; Baris I
Genet Test; 2007; 11(4):463-6. PubMed ID: 18294066
[TBL] [Abstract][Full Text] [Related]
12. Melting point assay for the JAK2 V617F mutation, comparison with amplification refractory mutation system (ARMS) in diagnostic samples, and implications for daily routine.
Ochsenreither S; Reinwald M; Thiel E; Burmeister T
Mol Diagn Ther; 2010 Jun; 14(3):185-90. PubMed ID: 20560681
[TBL] [Abstract][Full Text] [Related]
13. Detection of the JAK2 mutation in myeloproliferative neoplasms by asymmetric PCR with unlabeled probe and high-resolution melt analysis.
Cao HC; Lin J; Qian J; Yao DM; Li Y; Yang J; Chen Q; Chai HY; Xiao GF
J Clin Lab Anal; 2011; 25(4):300-4. PubMed ID: 21786333
[TBL] [Abstract][Full Text] [Related]
14. Validating the Sensitivity of High-Resolution Melting Analysis for JAK2 V617F Mutation in the Clinical Setting.
Lin CY; Ho CM; Tamamyan G; Yang SF; Peng CT; Chang JG
J Clin Lab Anal; 2016 Nov; 30(6):838-844. PubMed ID: 27169616
[TBL] [Abstract][Full Text] [Related]
15. Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection.
Zapparoli GV; Jorissen RN; Hewitt CA; McBean M; Westerman DA; Dobrovic A
BMC Cancer; 2013 Apr; 13():206. PubMed ID: 23617802
[TBL] [Abstract][Full Text] [Related]
16. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
[TBL] [Abstract][Full Text] [Related]
17. Design and application of a novel PNA probe for the detection at single cell level of JAK2V617F mutation in Myeloproliferative Neoplasms.
Bracco E; Rosso V; Serra A; Carnuccio F; Gaidano V; Nicoli P; Musto P; Saglio G; Frassoni F; Cilloni D
BMC Cancer; 2013 Jul; 13():348. PubMed ID: 23865766
[TBL] [Abstract][Full Text] [Related]
18. Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders.
Chen Q; Lu P; Jones AV; Cross NC; Silver RT; Wang YL
J Mol Diagn; 2007 Apr; 9(2):272-6. PubMed ID: 17384221
[TBL] [Abstract][Full Text] [Related]
19. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
[TBL] [Abstract][Full Text] [Related]
20. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
